Komori
Solasia Pharma K.K. (4597) · InitiativeRestated

Strengthening Internal Controls, Risk Management and Compliance

First written in FY2016. 2 of 5 entries say "Advanced", first in FY2017. Latest entry: FY2025.

5entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2017 – FY2021RestatedFY2022 – FY20252017: 120172018: 120182019: 020192020: 020202021: 020212022: 120222023: 120232024: 020242025: 020252026: 1
Same theme, other companies
Integrated Strengthening of Internal Controls, Corporate Governance and ComplianceA theme 354 companies write about · 2 as a headwind · 353 as a tailwind

102 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 355 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025RestatedAnnual report

    「当社は業務の適正性を確保するための体制として、取締役会にて、「内部統制システムの整備に関する基本方針」を定め、主に以下の事項について決議しています。」

    取締役会による内部統制基本方針、法令遵守、子会社を含む監査及びリスク管理の体制を継続している。
  2. FY2022RestatedAnnual report

    「当社は業務の適正性を確保するための体制として、取締役会にて、「内部統制システムの整備に関する基本方針」を定め、主に以下の事項について決議しています。」

    取締役会による内部統制基本方針、子会社を含む監査及びリスク管理の体制を継続している。
  3. FY2021AdvancedAnnual report

    「当社は、当社及び当社子会社の取締役及び監査役並びに管理職従業員(以下「役員等」という。)を被保険者とする役員等賠償責任保険(D&O保険)契約を締結しております。」

    内部統制・リスク管理の取り組みとして、取締役、監査役及び管理職従業員を対象とする役員等賠償責任保険契約の締結を開示した。一定の免責事由も設けている。
  4. FY2017AdvancedAnnual report

    「当社は業務の適正性を確保するための体制として、取締役会にて、「内部統制システムの整備に関する基本方針」を定め、主に以下の事項について決議しています。」

    取締役会による内部統制システムの基本方針、全社・子会社を対象とする内部監査、年1回以上のリスク調査など、上場後の統制・監査体制を具体化している。
  5. FY2016First statedAnnual report

    「The Company has established rules for crisis management, with the prevention of management crises and response when they occur as the principal objectives of risk management. The representative director and president is designated as the chief officer responsible for crisis management, and all employees are required to manage crises within their respective areas of responsibility.」

    The Company has established systems for internal audits, audit and supervisory committee audits, crisis management, legal compliance and corporate ethics, and plans to conduct risk assessments of each department at least once a year.
Moved together

"Business model based on in-licensing, clinical development and out-licensing" moved the same way as this thread, in the same document, in 2 of its 5 moves.

22222★12345
  1. ★This thread
  2. 1Business model based on in-licensing, clinical development and out-licensing2×
  3. 2Expansion of the New Development Pipeline2×
  4. 3Funding to Maintain the Business Foundation and Continue Development2×
  5. 4Dependence on Licensing, Outsourcing and Sales Partnerships2×
  6. 5Building a Direct Sales Network in Major Chinese Cities2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Internal Controls, Risk Management and Compliance | Solasia Pharma K.K. (4597) | Komori